Parametriline

Parametriline is a synthetic compound that belongs to the class of tricyclic antidepressants. It was developed in the 1960s and was initially marketed under the brand name Parnate. The drug is structurally related to imipramine and has a similar mechanism of action, primarily by inhibiting the reuptake of serotonin and norepinephrine in the brain.

Parametriline is primarily used for the treatment of major depressive disorder, as well as for the management of anxiety and panic disorders. It is typically prescribed in the form of tablets, with doses ranging from 25 to 100 mg per day. The drug is usually taken once or twice daily, with or without food.

Like other tricyclic antidepressants, parametriline has several side effects, including dry mouth, constipation, dizziness, and blurred vision. It may also cause drowsiness, which can impair cognitive function and motor skills. Serious side effects are rare but can include seizures, heart problems, and an increased risk of suicidal thoughts in young adults.

Parametriline is generally considered to be less effective than newer antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), and is less commonly prescribed today. However, it may still be used in certain situations, such as when other antidepressants have been ineffective or when a patient has a history of seizures. As with any medication, the use of parametriline should be carefully monitored by a healthcare professional.